Common TitleHBV-17: Heplisav-B versus Engerix-B in CKD
Official Title An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)
Phase Phase III
ClinicalTrials.gov NCT00985426
Treatments
Heplisav-B
Heplisav-B
Tradename:Heplisav-BOther Names:Hepatitis B Vaccine (Recombinant) Adjuvanted, HepB-CpGClass:Vaccines (HBV)Funding
IndustryDynavax Technologies Corporation